Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10323755" target="_blank" >RIV/00669806:_____/16:10323755 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/16:00090469 RIV/00216208:11140/16:10323755 RIV/00216208:11310/16:10323755
Result on the web
<a href="http://dx.doi.org/10.4149/318_151001N512" target="_blank" >http://dx.doi.org/10.4149/318_151001N512</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/318_151001N512" target="_blank" >10.4149/318_151001N512</a>
Alternative languages
Result language
angličtina
Original language name
Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib
Original language description
Molecular targeted therapy based on tyrosine kinase inhibitors (TKI), directed at epidermal growth factor receptor (EGFR) is one of the novel effective agents in management of advanced-stage of Non Small Cell Lung cancer (NSCLC). However several candidate predictors have been extensively studied, apart from activating EGFR gene mutations, no reliable biochemical or molecular predictors of response to erlotinib have been validated. The aim of our retrospective study was to evaluate the association of baseline serum albumin with outcomes in a large cohort of patients with advanced-stage NSCLC treated with erlotinib. Clinical data of 457 patients with locally-advanced (III B) or metastatic stage (IV) NSCLC treated with erlotinib were analysed.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neoplasma
ISSN
0028-2685
e-ISSN
—
Volume of the periodical
63
Issue of the periodical within the volume
3
Country of publishing house
SK - SLOVAKIA
Number of pages
6
Pages from-to
471-476
UT code for WoS article
000377058000018
EID of the result in the Scopus database
2-s2.0-84969645856